Acute myeloid leukemia: current progress and future directions

Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Farhad Ravandi(The University of Texas MD Anderson Cancer Center)

Blood Cancer Journal

February 22, 2021

10.1038/s41408-021-00425-3

Cited by 750

Related Papers

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

|Leukemia|2016|849

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

|Blood|2007|744

A phase 1 study of AMG 900, an orally administered pan‐aurora kinase inhibitor, in adult patients with acute myeloid leukemia

|American Journal of Hematology|2017|35

A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia

|Acta Haematologica|2018|18